Treatment of tardive dyskinesia in mammals

Patent 4425363 Issued on January 10, 1984. Estimated Expiration Date:

July 6, 2002. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

3819706

3885046

Inventor

Stern, Warren C.

Application

No. 06/395118 filed on 07/06/1982

US Classes:

514/649Amino nitrogen attached to aryl ring or aryl ring system by an acyclic carbon or acyclic chain

Examiners

Primary: Friedman, Stanley J.

Attorney, Agent or Firm

Gammons; Robert T.

International Class

A61K 31/135 (20060101)

Abstract

A method of Treatment of Tardive Dyskinesia (TD) in humans by the administration of the compound of the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof in a non-toxic, effective therapeutic amount (calculated as base) to a human in need thereof.

Other References

Ferris et al., Studies Concerning the Mechanism of The/Antidepressant Activity of Bupropion, J. Clin. Psychiatry, (1982)
Laakmann et al., Life Sciences, vol. 30, pp. 1725-1732, (1982), Pergamon Press
Butz et al., Inpress: Jour. Exp. Pharmacology of Therapeutics, (1982), The Relationship Between Bupropion Disposition & Dopamine Uptake in Rats and Mice
Ferris et al., Typical & Atypical Antidepressants, Molecular Mechanisms, Raven Press, New York, (1982), pp. 277-286
Ferris et al., Drug Development Research 1: 21-35, (1981)
Soroko et al., Communications, J. Pharm. Pharmac., (1977), 29, 767-770
Canning et al., Brit. Jour. of Pharmacology, (1979): 66 104-105
Whiteman et al., Jour. of Clin. Psychiatry, (1982), Failure of Bupropion to Affect Prolacter or Growth Hormone
Pharmacological and Biochemical Properties of Drug Substances, vol. 3, "Bupropion", Maxwell et al., Amer. Pharm. Ass. Academy of Pharm. Sciences Publish